IP Library › Granted Patent US 8,906,342
Granted Patent B2
US 8,906,342 · App. 14/052,905 · Granted Dec 9, 2014

Compositions against cancer antigen LIV-1 and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,906,342
App. No.
14/052,905
Granted
Dec 9, 2014
Kind
B2
Abstract

Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.

Claims (17)

1. A monoclonal antibody that specifically binds to a protein having the amino acid sequence of SEQ ID NO:2, wherein the antibody comprises the complementary determining regions (CDRs) of the heavy chain variable domain amino acid sequence shown in SEQ ID NO:3, and the CDRs of the light chain variable domain amino acid sequence shown in SEQ ID NO:4; or a chimeric or humanized form thereof.

2. The antibody of claim 1 , wherein the antibody is a humanized form of the antibody.

3. The antibody of claim 1 , which comprises a heavy chain variable region having the amino acid sequence of SEQ ID NO:3 and a light chain variable region having the amino acid sequence of SEQ ID NO:4.

4. The antibody of claim 1 , wherein the antibody is an antigen-binding fragment.

5. The antibody of claim 1 , wherein the antibody is conjugated to an effector component.

6. The antibody of claim 5 , wherein the effector component is selected from the group consisting of a fluorescent label, a radioisotope or a cytotoxic chemical.

7. The antibody of claim 6 , wherein the cytotoxic chemical is auristatin-E or monomethyl auristatin E.

8. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the antibody of claim 1 .

9. The pharmaceutical composition of claim 8 , wherein the antibody is an antigen-binding fragment.

10. The pharmaceutical composition of claim 8 , wherein the antibody is conjugated to an effector component comprising a radioisotope or a cytotoxic chemical.

11. The pharmaceutical composition of claim 10 , wherein the cytotoxic chemical is auristatin-E or monomethyl auristatin E.

12. A method of treating an individual with prostate or breast cancer, wherein the method comprises administering a therapeutically effective dose of the antibody of claim 1 .

13. The method of claim 12 , wherein the antibody is a chimeric antibody.

14. The method of claim 12 , wherein the antibody is a humanized antibody.

15. The method of claim 12 , wherein the antibody is an antigen-binding fragment.

16. The method of claim 12 , wherein the antibody is conjugated to an effector component comprising a radioisotope or a cytotoxic chemical.

17. The method of claim 16 , wherein the cytotoxic chemical is auristatin-E or monomethyl auristatin E.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2014
From: LAW, DEBBIE; GISH, KURT
To: ABBVIE BIOTHERAPEUTICS INC.
Reel/Frame 032730/0843 →